Physicochemical studies on the interaction of serum albumin with pulmonary surfactant extract in films and bulk bilayer phase

Nag, Kaushik; Vidyashankar, Sangeetha; Devraj, Ravi; Garcia, Mauricia Fritzen; Panda, Amiya Kumar

doi:10.1016/j.jcis.2010.08.058

Cited by 11 publications

(7 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our information this is the first study that shows superiority of a surfactant preparation for inactivation in vivo . Albumin was chosen as inhibitor since it is well studied as inducer of surfactant inactivation in vitro and in vivo [28], [29]. In addition, albumin is a plasma protein and part of the inflammatory cascade induced by various stimuli such as mechanical ventilation or infection [30], [31].…”

Section: Discussionmentioning

confidence: 99%

New Surfactant with SP-B and C Analogs Gives Survival Benefit after Inactivation in Preterm Lambs

et al. 2012

View full text Add to dashboard Cite

BackgroundRespiratory distress syndrome in preterm babies is caused by a pulmonary surfactant deficiency, but also by its inactivation due to various conditions, including plasma protein leakage. Surfactant replacement therapy is well established, but clinical observations and in vitro experiments suggested that its efficacy may be impaired by inactivation. A new synthetic surfactant (CHF 5633), containing synthetic surfactant protein B and C analogs, has shown comparable effects on oxygenation in ventilated preterm rabbits versus Poractant alfa, but superior resistance against inactivation in vitro. We hypothesized that CHF 5633 is also resistant to inactivation by serum albumin in vivo.Methodology/Principal FindingsNineteen preterm lambs of 127 days gestational age (term = 150 days) received CHF 5633 or Poractant alfa and were ventilated for 48 hours. Ninety minutes after birth, the animals received albumin with CHF 5633 or Poractant alfa. Animals received additional surfactant if PaO2 dropped below 100 mmHg. A pressure volume curve was done post mortem and markers of pulmonary inflammation, surfactant content and biophysiology, and lung histology were assessed. CHF 5633 treatment resulted in improved arterial pH, oxygenation and ventilation efficiency index. The survival rate was significantly higher after CHF 5633 treatment (5/7) than after Poractant alfa (1/8) after 48 hours of ventilation. Biophysical examination of the surfactant recovered from bronchoalveolar lavages revealed that films formed by CHF 5633-treated animals reached low surface tensions in a wider range of compression rates than films from Poractant alfa-treated animals.ConclusionsFor the first time a synthetic surfactant containing both surfactant protein B and C analogs showed significant benefit over animal derived surfactant in an in vivo model of surfactant inactivation in premature lambs.

show abstract

Section: Discussionmentioning

confidence: 99%

New Surfactant with SP-B and C Analogs Gives Survival Benefit after Inactivation in Preterm Lambs

et al. 2012

View full text Add to dashboard Cite

show abstract

“…6 a-c . The CH 2 , CH 3 , and C-C skeletal bands could clearly be defined, as well as temperature dependent shifts in some of the bands which allow for a relative measurement of the phase transition of BLES and BLES with additives could be monitored 16,17 . This phase change monitoring allow correlating the structural features observed in films due to the 2D lateral phase transitions induced by compression with those that occurred in the bulk bilayer material with the change of temperature, since the films were formed from such bilayer dispersions.…”

Section: Raman Spectroscopy Studiesmentioning

confidence: 99%

“…These trends were consistent with a change in conformation of the lipids as a function of temperature, where an increased fluidity of the hydrocarbon chain or gauche conformation had been observed at higher temperatures. At lower temperatures [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25] however, the hydrocarbon…”

Section: Raman Spectroscopy Studiesmentioning

confidence: 99%

“…The concentration of serum as little as 2 wt , added to BLES dispersions, could inactivate BLES in ways that would take tenfold soluble protein concentrations or 500-1000 wt 15,16,22 . This gave some credence to the idea that there may be some other factors in serum that cause such potent inhibition, perhaps a lipid-like, nonprotein material.…”

Section: Serum Lipids and Proteinsmentioning

confidence: 99%

“…Various previous studies have used the method to study lipid films as well as those with serum proteins 7,11,15,16,27 . Our study examined the effects of serum or serum components in the formation of BLES domain.…”

Section: Structure and Dysfunctionmentioning

confidence: 99%

See 2 more Smart Citations

Effect of Serum, Cholesterol and Low Density Lipoprotein on the Functionality and Structure of Lung Surfactant Films

et al. 2014

Self Cite

View full text Add to dashboard Cite

Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases

Anderson

Grimmett

Domalewski

et al. 2019

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

Respiratory illnesses are prevalent around the world, and inhalation‐based therapies provide an attractive, noninvasive means of directly delivering therapeutic agents to their site of action to improve treatment efficacy and limit adverse systemic side effects. Recent trends in medicine and nanoscience have prompted the development of inhalable nanomedicines to further enhance effectiveness, patient compliance, and quality of life for people suffering from lung cancer, chronic pulmonary diseases, and tuberculosis. Herein, we discuss recent advancements in the development of inhalable nanomaterial‐based drug delivery systems and analyze several representative systems to illustrate their key design principles that can translate to improved therapeutic efficacy for prevalent respiratory diseases. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Respiratory Disease

show abstract

Physicochemical studies on the interaction of serum albumin with pulmonary surfactant extract in films and bulk bilayer phase

Cited by 11 publications

References 64 publications

New Surfactant with SP-B and C Analogs Gives Survival Benefit after Inactivation in Preterm Lambs

New Surfactant with SP-B and C Analogs Gives Survival Benefit after Inactivation in Preterm Lambs

Effect of Serum, Cholesterol and Low Density Lipoprotein on the Functionality and Structure of Lung Surfactant Films

Inhalable nanotherapeutics to improve treatment efficacy for common lung diseases

Contact Info

Product

Resources

About